Document Detail

Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center.
MedLine Citation:
PMID:  23334269     Owner:  NLM     Status:  Publisher    
Thalidomide, lenalidomide and bortezomib have increasingly been incorporated in first-line induction therapies for multiple myeloma. Concerns regarding the impact of these agents, especially lenalidomide, on stem cell mobilization prompted us to re-evaluate the risk factors that impact mobilization, including exposure to novel induction regimens. Among 317 patients who proceeded to stem cell collection after induction therapy between 2000 and 2009, the rate of mobilization failure, defined as the inability to collect 5 × 10(6) CD34+ cells/kg following the first collection attempt, was 13%. By multivariate analysis, independent risk factors associated with mobilization failure included older age (P=0.04), lower platelet count (P=0.002) and use of single-agent G-CSF for mobilization (P<0.0001). When considering for outcome measurement stem cell collection efficiency measured by the number of CD34+ cells yielded per pheresis performed during first collection attempt, lower platelet count, use of single-agent G-CSF and older age were also associated with lower efficiency. In this population mobilized mostly with cyclophosphamide and G-CSF, the use of lenalidomide during induction was not associated with a lower stem cell collection efficiency by multivariate analysis. The data support the current International Multiple Myeloma Working Group guidelines recommending the use of cyclophosphamide and G-CSF based mobilization for patients previously exposed to lenalidomide.Bone Marrow Transplantation advance online publication, 21 January 2013; doi:10.1038/bmt.2012.281.
M Pozotrigo; N Adel; H Landau; A Lesokhin; N Lendvai; D J Chung; D Chimento; E Riedel; X Chen; L Reich; R Comenzo; S Giralt; H Hassoun
Related Documents :
24302539 - Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progress...
24883199 - Administration of a nondepleting anti-cd25 monoclonal antibody reduces disease severity...
24055739 - Chicken slamf4 (cd244, 2b4), a receptor expressed on thrombocytes, monocytes, nk cells,...
23409799 - Pralatrexate : evaluation of clinical efficacy and toxicity in t-cell lymphoma.
23836489 - Surface cd24 distinguishes between low differentiated and transit-amplifying cells in t...
22961659 - A canonical vγ4vδ4+ γδ t cell population with distinct stimulation requirements whi...
17947359 - Increased p2x7 receptor expression and function in thyroid papillary cancer: a new pote...
7596169 - Il-4 stimulates the growth of chronic myelomonocytic leukemia cells (cmmol) once leukem...
12704799 - Proliferation and differentiation of osteoblasts and adipocytes in rat bone marrow stro...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-21
Journal Detail:
Title:  Bone marrow transplantation     Volume:  -     ISSN:  1476-5365     ISO Abbreviation:  Bone Marrow Transplant.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8702459     Medline TA:  Bone Marrow Transplant     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical and microbiological results following nonsurgical periodontal therapy with or without local...
Next Document:  Potential adult sibling stem cell donors' perceptions and opinions regarding an information and care...